Bloomsbury Genetic Therapies

General Information

Company Name

Founded Year

2021

Location (Offices)

London, United Kingdom +1

Founders / Decision Makers

Number of Employees

Industries

Biopharma, Biotechnology, Pharmaceutical

Funding Stage

Seed

Social Media

Bloomsbury Genetic Therapies - Company Profile

Bloomsbury Genetic Therapies is a United Kingdom-based clinical-stage biotechnology company, focused on developing potentially curative treatments for patients with rare neurological and metabolic diseases through gene therapy technologies. The company was spun out of University College London and officially launched in October 2022 with an initial £5.00M Seed Round investment from the UCL Technology Fund. Bloomsbury is committed to delivering the promise of gene therapy and is currently building a pipeline of highly differentiated first- or best-in-class programs within the biopharma, biotechnology, and pharmaceutical industries.

Taxonomy: gene therapy, neurological diseases, metabolic diseases, clinical-stage, rare diseases, University College London, spin-out, UCL Technology Fund, pipeline development, first-in-class programs, best-in-class treatments